miR-100 Reverses Cisplatin Resistance in Breast Cancer by Suppressing HAX-1

Background/Aims: Breast cancer (BC) is the most common cancer in women worldwide. Despite great advancements in cancer therapy in recent years, surgery and chemotherapy are still the mainstays of BC treatment. However, cancer cells usually develop mechanisms to evade cell death induced by chemothera...

詳細記述

書誌詳細
出版年:Cellular Physiology and Biochemistry
主要な著者: Guojun Wu, Wenhong Zhou, Xiaohua Pan, Yongjie Sun, Hao Xu, Peng Shi, Jiyu Li, Ling Gao, Xingsong Tian
フォーマット: 論文
言語:英語
出版事項: Cell Physiol Biochem Press GmbH & Co KG 2018-07-01
主題:
オンライン・アクセス:https://www.karger.com/Article/FullText/491476

類似資料